ScripsAmerica, Inc. (SCRCQ) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerScripsAmerica, Inc. (SCRCQ) trades at $0.0001. ScripsAmerica, Inc. focuses on developing and selling non-sterile topical and transdermal pain creams, along with providing pharmacy dispensing, billing, and administrative services. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for SCRCQ: SCRCQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
ScripsAmerica, Inc. (SCRCQ) Healthcare & Pipeline Overview
ScripsAmerica, Inc., operating in the healthcare sector, develops and sells topical pain creams while providing pharmacy services. Facing financial challenges, including a Chapter 7 bankruptcy conversion, the company navigates a competitive pharmaceutical landscape with a focus on niche product offerings and service provision to independent pharmacies and medical providers.
What Is the Investment Thesis for SCRCQ?
Investing in ScripsAmerica, Inc. (SCRCQ) presents substantial risks due to its Chapter 7 bankruptcy conversion in 2017. The company's market capitalization is effectively zero, and its negative P/E ratio and profit margin of -15.3% reflect ongoing financial difficulties. While the gross margin of 89.4% suggests potential profitability in its core operations, the company's future is uncertain given its current financial state. Any investment decision would require careful consideration of the risks associated with OTC-listed companies and the implications of the bankruptcy proceedings. The company's beta of -54.25 indicates an inverse correlation with the market, but this metric may be unreliable given the company's distressed state.
Based on FMP financials and quantitative analysis
SCRCQ Key Highlights
Gross Margin of 89.4% indicates potential profitability in core operations despite overall financial struggles.
- Chapter 7 Bankruptcy Conversion in 2017 signals significant financial distress and liquidation proceedings.
- Negative P/E Ratio reflects ongoing losses and lack of profitability.
- Profit Margin of -15.3% highlights the company's inability to generate profits from its revenue.
- Market Cap of $0.00B indicates minimal investor confidence and potential delisting.
Who Are SCRCQ's Competitors?
SCRCQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RDGT Ridgetech Inc. | $0.87 | +2.81% | 33 5-pillar | |
| ACH Accendra Health, Inc. | $0.51 | -9.43% | $38.7M | — |
| PBH Prestige Consumer Healthcare Inc. | $45.26 | +1.09% | $2.14B | 63 5-pillar |
| GRDN Guardian Pharmacy Services, Inc. | $42.38 | +3.77% | $2.68B | 97 5-pillar |
| HSIC Henry Schein, Inc. | $84.88 | -0.06% | $9.67B | 73 5-pillar |
| CAH Cardinal Health, Inc. | $228.30 | -0.78% | $53.5B | 88 5-pillar |
| COR Cencora, Inc. | $309.05 | -0.24% | $60.1B | 81 5-pillar |
| MCK McKesson Corporation | $902.28 | +0.38% | $106B | 90 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SCRCQ's Key Strengths?
Established relationships with independent pharmacies.
- Focus on niche market of topical pain relief.
- High gross margin (89.4%) on product sales.
What Are SCRCQ's Weaknesses?
Chapter 7 bankruptcy conversion.
- Limited financial resources.
- Small market capitalization.
What Are the Key Risks for SCRCQ?
Financial-distress signal — its Altman Z-Score of -1.53 sits in the distress zone (elevated bankruptcy risk).
- Chapter 7 bankruptcy proceedings leading to liquidation.
- Product liability claims related to topical pain creams.
- Inability to compete with larger pharmaceutical companies.
- Limited access to capital and funding.
- Changes in healthcare regulations impacting the company's business.
What Threats Does SCRCQ Face?
- Intense competition from larger pharmaceutical companies.
- Stringent regulatory requirements.
- Potential product liability claims.
What Are SCRCQ's Competitive Advantages?
- Established relationships with independent pharmacies.
- Proprietary formulations of topical pain creams (if any).
- Distribution network for pharmaceutical products.
What Does SCRCQ Do?
Founded in 2008 and based in Clifton, New Jersey, ScripsAmerica, Inc. specializes in the development and sale of non-sterile topical and transdermal pain creams. The company also extends its services to include pharmacy dispensing for individual doctors, along with billing and administrative support for independent pharmacies. Additionally, ScripsAmerica distributes pharmaceutical products to a network of independent pharmacies and other medical providers. ScripsAmerica aimed to carve a niche in the pharmaceutical market by focusing on pain management solutions and support services for independent pharmacies. However, the company faced significant financial headwinds, leading to a voluntary petition for reorganization under Chapter 11 in September 2016. Subsequently, in February 2017, the bankruptcy case was converted to Chapter 7, indicating a shift towards liquidation. The company's history reflects the challenges of smaller pharmaceutical companies in a highly competitive and regulated industry.
What Products and Services Does SCRCQ Offer?
- Develops non-sterile topical pain creams.
- Sells transdermal pain creams.
- Provides pharmacy dispensing services for individual doctors.
- Offers billing and administrative services to independent pharmacies.
- Distributes pharmaceutical products to independent pharmacies.
- Supplies pharmaceutical products to other medical providers.
How Does SCRCQ Make Money?
- Generates revenue through the sale of topical and transdermal pain creams.
- Earns fees by providing pharmacy dispensing services to doctors.
- Collects fees for billing and administrative services offered to independent pharmacies.
What Industry Does SCRCQ Operate In?
ScripsAmerica, Inc. operates within the medical pharmaceutical industry, a sector characterized by intense competition, stringent regulations, and high research and development costs. The market for pain management solutions is substantial, driven by an aging population and increasing prevalence of chronic pain conditions. However, ScripsAmerica faces competition from larger, more established pharmaceutical companies with greater resources and broader product portfolios. The company's focus on topical pain creams and services for independent pharmacies positions it within a niche segment of the market, but its financial difficulties present a significant challenge to its long-term viability.
Who Are SCRCQ's Key Customers?
- Individual doctors requiring pharmacy dispensing services.
- Independent pharmacies seeking billing and administrative support.
- Patients using topical and transdermal pain relief products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
ScripsAmerica, Inc. operates in the Healthcare sector. It is headquartered in Clifton, US. The company is led by CEO Brian Ettinger. SCRCQ has traded publicly since 2012.
Key Financial Metrics
Return on equity for ScripsAmerica, Inc. stands at 162.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -83.8%, showing how much profit it generates from its asset base. A current ratio of 0.67 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
ScripsAmerica, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.53 places it in the distress zone, a signal of elevated financial risk.
SCRCQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
SCRCQ Latest News
No recent news available for SCRCQ.
SCRCQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SCRCQ.
Price Targets
Wall Street price target analysis for SCRCQ.
SCRCQ MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SCRCQ; grades run from A+ (80-100) to F (below 30).
Leadership: Brian Ettinger
CEO
Brian Ettinger serves as the CEO of ScripsAmerica, Inc., managing a team of 21 employees. As CEO, he is responsible for overseeing the company's strategic direction, operations, and financial performance. His leadership is critical in navigating the company's current financial challenges and exploring potential avenues for recovery.
Track Record: Due to the company's financial difficulties and Chapter 7 bankruptcy conversion, assessing Brian Ettinger's track record is challenging. Key milestones and strategic decisions during his tenure are difficult to evaluate in light of the company's overall performance. His leadership is currently focused on managing the liquidation process and fulfilling the company's obligations to creditors.
SCRCQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ScripsAmerica, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for fraud, lack of transparency, and limited liquidity.
- OTC Tier: OTC Other
- Limited Liquidity: Difficulty in buying or selling shares due to low trading volume.
- Lack of Transparency: Unknown disclosure status makes it difficult to assess the company's financial health.
- Potential for Fraud: Higher risk of fraudulent activity compared to companies on major exchanges.
- Bankruptcy Risk: Chapter 7 bankruptcy conversion indicates a high risk of liquidation and loss of investment.
- Limited Regulatory Oversight: Less regulatory scrutiny compared to companies on major exchanges.
- Verify the company's current legal status and bankruptcy proceedings.
- Assess the company's assets and liabilities.
- Review any available financial statements or disclosures.
- Research the background and experience of the company's management team.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC Other tier companies.
- Consult with a financial advisor before making any investment decisions.
- Operational History: The company has been in operation since 2008.
- Focus on Healthcare: Operates within the healthcare sector, providing pharmaceutical products and services.
- Established Relationships: Has established relationships with independent pharmacies and medical providers.
Common Questions About SCRCQ (Healthcare)
What are the main risks for SCRCQ?
The primary risk for ScripsAmerica, Inc. is its Chapter 7 bankruptcy conversion, which indicates a high likelihood of liquidation and potential loss of investment.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's OTC listing and bankruptcy proceedings.
- Financial data may not be current or fully accurate.